2[2]Gibbons RJJ,Antmrn EM,Alpert JS,et al. ACC/AHA /ESC guidelines for the management of patients with atrial fibrillation [J]. Eur Heart J, 2001,22: 1852 -1923 被引量：1
3[3]Farshi R,Kistner D,Sarma JSM,et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a cross over open - label study of five drug regimens [ J ]. J Am Coll Cardiol,1999,33: 304 - 310 被引量：1
5[5]Zoble RG, Brewington J, Olukotun AY, et al. Comparative effects of nadolol - digoxin combination therapy and digoxin monotherpy for chronic atrial fibrillation[J ]. Am J Cardiol, 1987,60: 39D- 45D 被引量：1
6[6]Redfors A. Plasma digoxin concertration: its relation to digoxin dosage and clinical effects in patients with atrial fibrillation[ J ]. Br Heart J, 1972,34: 383 - 391 被引量：1
7[7]Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation[ J ]. Chest, 1983,83:491 - 499 被引量：1
8[8]Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of "therapeutic serum levels of digoxin in controlling the ventricular rate in atrial fibrillation[J]. Am J Cardiol,1975,35:651 - 655 被引量：1
9[9]Lewis RV. Irvine N, McDevitt DG. Relationship between heart rate,exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem [ J ]. Eur Heart J,1998,9: 777 - 781 被引量：1
10[10]Ang EL. Chan WL, Cleland JGF. et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation[J]. Br Heart J ,1990,64:256 - 260 被引量：1
